Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Operating Margin (2016 - 2025)

Haemonetics has reported Operating Margin over the past 17 years, most recently at 19.88% for Q4 2025.

  • For Q4 2025, Operating Margin rose 295.0% year-over-year to 19.88%; the TTM value through Dec 2025 reached 19.05%, up 591.0%, while the annual FY2025 figure was 16.3%, 370.0% up from the prior year.
  • Operating Margin for Q4 2025 was 19.88% at Haemonetics, up from 17.87% in the prior quarter.
  • Over five years, Operating Margin peaked at 21.58% in Q1 2025 and troughed at 9.41% in Q2 2021.
  • A 5-year average of 12.31% and a median of 13.7% in 2022 define the central range for Operating Margin.
  • Biggest five-year swings in Operating Margin: plummeted -2031bps in 2021 and later skyrocketed 1665bps in 2022.
  • Year by year, Operating Margin stood at 10.22% in 2021, then surged by 39bps to 14.18% in 2022, then dropped by -4bps to 13.67% in 2023, then rose by 24bps to 16.94% in 2024, then rose by 17bps to 19.88% in 2025.
  • Business Quant data shows Operating Margin for HAE at 19.88% in Q4 2025, 17.87% in Q3 2025, and 16.76% in Q2 2025.